Simplex Trading, LLC Relay Therapeutics, Inc. Transaction History

Simplex Trading, LLC

$3.35 Billion
Q1 2024

A detailed history of Simplex Trading, LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 150 shares of RLAY stock, worth $954. This represents 0.0% of its overall portfolio holdings.

Number of Shares

150

Holding current value

$954

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$7.5 - $12.07 $1,125 - $1,810	150 New	150 $1,000
Q3 2023 Nov 01, 2023	BUY	$8.24 - $12.97 $19,388 - $30,518	2,353 Added 22.21%	12,945 $108,000
Q2 2023 Aug 04, 2023	BUY	$9.99 - $18.27 $25,064 - $45,839	2,509 Added 31.04%	10,592 $133,000
Q1 2023 Apr 27, 2023	BUY	$15.0 - $22.76 $111,180 - $168,697	7,412 Added 1104.62%	8,083 $133,000
Q4 2022 Feb 02, 2023	BUY	$14.16 - $24.02 $5,805 - $9,848	410 Added 157.09%	671 $10,000

Q3 2022 Nov 04, 2022	BUY	$18.07 - $31.37 $4,716 - $8,187	261 New	261 $5,000
Q2 2022 Aug 03, 2022	SELL	$13.31 - $34.88 $36,070 - $94,524	-2,710 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$20.26 - $32.36 $54,904 - $87,695	2,710 New	2,710 $81,000

Others Institutions Holding RLAY

# of Institutions

188

Shares Held

127M

Call Options Held

4.2K

Put Options Held

1.7K

Sb Investment Advisers (Uk) LTD London, X0

27.9M
Shares

$177 Million
2.29% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$75.1 Million
0.0% of portfolio
Black Rock Inc. New York, NY

9.8M
Shares

$62.3 Million
0.0% of portfolio
Casdin Capital, LLC New York, NY

7.42M
Shares

$47.2 Million
4.98% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.88M
Shares

$43.8 Million
0.01% of portfolio

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $765M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account